FDA Places REGENXBIO’s RGX-121 on Clinical Hold After Spine MRI Findings
FDA placed the RGX-121 program on clinical hold after asymptomatic spinal MRI findings were identified in five CAMPSIITE participants treated approximately three to six years earlier. REGENXBIO no longer expects to resubmit the RGX-121…
